Objective The objective of this study is to investigate the regulatory effects of traditional Astragaloside IV and its novel derivative，astragaloside formic acid (LS-102)，on the renal pathology of obesity-related nephropathy，and to conduct a control ex⁃ periment. Methods Male C57BL/6J mice fed with high fat were randomly divided into 5 groups. HFD group was fed with high fat diet for 4 weeks. LAS group was fed with low concentration Astragaloside IV (10mg/kg) and high fat diet for 4 weeks. HAS group was fed with high concentration Astragaloside IV (40mg/kg) and high fat diet for 4 weeks. L102 group was given low concentration LS-102 (10mg/kg) by intragastric administration，and continued to be fed high-fat diet for 4 weeks. H102 group was given high concentration LS-102 (40 mg/kg) by intragastric administration，and continued to be fed high-fat diet for 4 weeks.The habits and coat color changes of mice in different groups were observed. HE staining，PAS staining and Masson staining were used to evaluate the renal pathological changes of mice in each experimental group.Quantitative analysis was performed using Image-Pro Plus 6.0 software. Results Both tradi⁃ tional Astragaloside IV and astragaloside formate LS-102 could improve the habits and hair color of mice，and both could improve the pathological changes of kidney in obesity-related nephropathy mice. The effect of LS-102 was superior to Astragaloside IV，and the ef⁃ fect of LS-102 on improving the pathological changes of kidney in obesity-related nephropathy was concentration-dependent. Conclusion Astragalus formic acid（LS-102），showed better protective effect than traditional Astragaloside IV in pathological regulation of obesity-related nephropathy. It was suggested that LS-102 might be a new Chinese medicine preparation for the clinical treatment of obesity and its related diseases.